In addition, expression of the mutant KRAS gene correlates with a marked decrease in aspartate levels and increased asparagine levels due to upregulated ASNS expression, which indicated that ASNS might be a novel therapeutic target for KRAS-mutant CRC [28,29]. The gene discussed is ASNS; the disease is colorectal carcinoma.